A rare location for cardiac ... Comparison of the sternal wi ... Isolated insufficiency of th ... Acute massive pulmonary embo ... Giant asymptomatic pulmonary ... Aortic coarctation and desce ... Esophagitis and gastritis ar ... Surgical treatment of an iso ... Comparison of conventional e ... Removal of a missed guide wi ... View All

Effectiveness of directional ... Mitral valve replacement in ... Removal of a missed guide wi ... Surgical treatment of an iso ... Aortic coarctation and desce ... Comparison of conventional e ... Surgery of mitral valve dise ... PERSPECTIVE FROM the EDITOR ... A comparison of quality of l ... Isolated insufficiency of th ... View All

Back | Table of Contents | Full Text | PDF | Similar Articles |

Redo transcatheter aortic valve implantation: Our single-center experience and mid-term outcomes

Ahmet Anıl Başkurt¹, Sercan Karaoğlan², Hatice Özdamar³, Önercan Çakmak⁴, Hüseyin Dursun², Kaya Dayimi<sup>2

1</sup>Department of Cardiology, Bakırçay University, İzmir, Türkiye
²Department of Cardiology, Dokuz Eylül University Faculty of Medicine, İzmir, Türkiye
³Department of Cardiology, Tepecik Training and Research Hospital, İzmir, Türkiye
⁴Department of Cardiology, Dinar Hospital, Isparta, Türkiye

Keywords: Aortic stenosis, redo, transcatheter aortic valve implantation

---

Objectives: In this study, we present our mid-term outcomes on redo transcatheter aortic valve implantation (TAVI).

Patients and methods: Between June 2012 and May 2019, a total of eight TAVI-in-TAVI patients (2 males, 6 females; mean age: 73.8±3.9 years; range, 66 to 79 year) were retrospectively analyzed. All patients were evaluated for comorbidity, characteristics of the first TAVI valve, indications for redo-TAVI, transthoracic echocardiographic parameters, mortality, pacemaker requirement, and valve function during follow-up.

Results: Five (62.5%) of the patients required a redo-TAVI procedure due to severe aortic regurgitation, while three (37.5%) required a redo-TAVI procedure due to degeneration of the first TAVI valve. The first TAVI valves of the patients were two Portico™, four CoreValve™ and two Edwards SAPIEN™. In redo-TAVI procedures of the patients, four CoreValve™, two Portico™, and two MyVal™ valves were used. The median time after the first procedure was 62 months. One patient had hypertensive pulmonary edema during the procedure and was intubated, and in-hospital mortality occurred due to infectious causes during intensive care follow-up. There was no in-hospital mortality and no need for pacemaker in other patients. There was no mortality at a median follow-up of 31 months after redo-TAVI procedures.

Conclusion: Redo-TAVI procedure is a feasible intervention and can be successfully done in selected patients requiring reintervention due to valve degeneration or severe aortic regurgitation.

Back | Table of Contents | Full Text | PDF | Similar Articles |